Skip to Content

Adjuvant treatment with osimertinib in patients with stage IB-IIIA EGFR-positive NSCLC after complete tumor resection reduces the risk of relapse and death by 83%

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top